The systemic treatment of malignant pleural mesothelioma (MPM) in routine practice has remained unchanged since 2003, with almost a decade passing since any new treatment being approved for this disease. However, there are currently more novel agents in clinical trials than ever before, bringing hope that the next decade will see improvements in survival and other patient outcomes. This review will focus on systemic treatments for advanced disease, with an overview of current practice and a view to the future of chemotherapy and targeted therapies in mesothelioma. The use of chemotherapy as part of multimodality treatment for mesothelioma is covered in a companion paper in this issue and will not be addressed here.
No takes yet. Share an insight, caveat, or question.
Anna K. Nowak (2012) studied this question.